Gene therapy using AAV vectors

Drug Delivery System

Volumn 22, Issue 6, 2007, Pages 643-650

  Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

AAV vector; gene therapy; hemophilia; Parkinson's disease; serotype

Indexed keywords

EID: 77952563404     PISSN: 09135006     EISSN: 18812732     Source Type: Journal    
DOI: 10.2745/dds.22.643     Document Type: Article

References (36)

1. Summerford C, Samulski RJ: Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438-1445, 1998.
2. Qing K, Mah C, Hansen J, Zhou S, Dwarki V et al. : Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5: 71-77, 1999.
3. Summerford C, Bartlett JS, Samulski RJ: SVV5 integrin:a co-receptor for adeno-associated virus type 2 infection. Nat Med 5: 78-82, 1999.
4. Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai Y, Shimada T et al. : Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 79: 609-614, 2005.
5. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA: Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 75: 6884-6893, 2001.
6. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ: α2, 3 and α2, 6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol 80: 9093-9103, 2006.
7. Akache B, Grimm D, Pandey K, Yant SR, Xu H et al. : The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80: 9831-9836, 2006.
8. Pasquale GD, Davidson BL, Stein CS, Martins I, Scudiero D et al. : Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9: 1306-1312, 2003.
9. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L et al. : Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 5: 938-945, 1998.
10. Urabe M, Xin KQ, Obara Y, Nakakura T, Mizukami H et al. : Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression. Mol Ther 13: 823-828, 2006.
11. Shen Y. Muramatsu S, Ikeguchi, Fujimoto K, Fan D et al. : Triple transduction with adeno associated virus vectors expressing tyrosine hydroxylase, aromatic L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 11: 1509-1519, 2000.
12. Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR : Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 77: 3495-3504, 2003.
13. Nakai H, Montini E, Fuess S, Storm TA, Grompe M et al. : AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 34: 297-302, 2003.
14. Fan D, Ogawa M, Fujimoto K, Ikeguchi K, Ogasawara Y et al. : Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno associated virus vectors. Hum Gene Ther 9: 2527-2535, 1998.
15. Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM et al. : Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 18: 195-206, 2007.
16. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D et al. : Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 5: 56-63, 1999.
17. Riviere C, Danos O, Douar AM: Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 13: 1300-1308, 2006.
18. Pruchnic R, Cao B, Peterson ZQ, Xiao X, Li J et al. : The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum Gene Ther 11: 521-536, 2000.
19. Nakai H, Herzog RW, Hagstrom JN, Walter J, Kung SH et al. : Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 91: 4600-4607, 1998.
20. Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA et al. : Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 5: 64-70, 1999.
21. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ et al. : Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2: 619-623, 2000.
22. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W et al. : Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76: 791-801, 2002.
23. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J et al. : Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859, 2002.
24. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R et al. : Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78: 6381-6388, 2004.
25. Wu Z, Asokan A, Samulski RJ : Adeno-associated virus serotypes:vector toolkit for human gene therapy. Mol Ther 14: 316-327, 2006.
26. Nathwani AC, Gray JT, Ng CY, Zhou J, Spence Y et al. : Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107: 2653-2661, 2006.
27. Muramatsu S, Fujimoto K, Ikeguchi K, Shizuma N, Kawasaki K et al. : Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13: 345-354, 2002.
28. Wang L, Muramatsu S, Lu Y, Ikeguchi K, Fujimoto K et al. : Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 9: 381-389, 2002.
29. During MJ, Kaplitt MG, Stern MB, Eidelberg D: Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 10: 1589-1591, 2001.
30. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y et al. : Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298: 425-429, 2002.
31. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB et al. : Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24: 257-261, 2000.
32. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW et al. : AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101: 2963-2972, 2003.
33. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M et al. : Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347, 2006.
34. Takei Y, Mizukami H, Saga Y, Yoshimura I, Hasumi Y et al. : Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. Int J Cancer 120: 278-284, 2007.
35. Kohno T, Mizukami H, Suzuki M, Saga Y, Takei Y et al. : Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 63: 5091-5094, 2003.
36. Saga Y, Mizukami H, Suzuki M, Urabe M, Kume A et al. : Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther 8: 1450-1455, 2001.